BofA Securities Maintains Chemed(CHE.US) With Buy Rating, Maintains Target Price $708
Chemed Analyst Ratings
RBC Capital Maintains Chemed(CHE.US) With Buy Rating, Cuts Target Price to $633
RBC Capital Remains a Buy on Chemed (CHE)
Oppenheimer Maintains Chemed(CHE.US) With Buy Rating, Maintains Target Price $650
BofA Securities Maintains Chemed(CHE.US) With Buy Rating, Maintains Target Price $708
Oppenheimer Maintains Chemed(CHE.US) With Buy Rating, Maintains Target Price $650
Oppenheimer Sticks to Its Buy Rating for Chemed (CHE)
Oppenheimer Maintains Chemed(CHE.US) With Buy Rating, Maintains Target Price $650
Oppenheimer Maintains Chemed(CHE.US) With Buy Rating, Maintains Target Price $650
Oppenheimer Remains a Buy on Chemed (CHE)
Chemed Corp: A Buy Rating With Strong Vitas Fundamentals and Growth in Roto-Rooter Services
Royal Bank of Canada: Maintaining the Chemed (CHE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $712.00 to $697.00.
RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $697
Chemed Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Hookipa Pharma (HOOK), Chemed (CHE)
Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Acadia Healthcare (ACHC) and Taysha Gene Therapies (TSHA)
Chemed (CHE) Receives a Rating Update From a Top Analyst
Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)
Analysts Conflicted on These Healthcare Names: Chemed (CHE) and Alkermes (ALKS)